BPC-157 Complex

Every batch ships with a batch code printed on the vial. The matching independent lab report — identity, purity, and composition — independently lab-tested results — is linked on the product page and also available from your order page after purchase.

Sensitive peptides ship cold. Move them to a fridge on arrival (2–8 °C) unless the product page states otherwise. Lyophilised vials can tolerate short transit at ambient temperature but should not be left unrefrigerated for extended periods once delivered.

Orders placed before 14:00 CET Monday–Friday ship the same business day from our European fulfilment centre in The Hague, Netherlands. Standard tracked EU delivery arrives in 2–4 business days; express options are available at checkout.

BPC-157 is a 15-amino-acid pentadecapeptide studied for localised soft-tissue and gut-lining repair via VEGFR-2 and nitric-oxide signalling, while TB-500 (Thymosin beta-4 fragment) is studied for systemic effects on cell migration and actin regulation. Both are sold strictly as research compounds — neither is approved by the EMA or FDA for human use, and both have been on the WADA prohibited list since 2022.

BPC-157 is not approved by the European Medicines Agency for any medical indication, so it cannot be prescribed in any EU member state. It is sold across Europe — including from our Dutch fulfilment centre — as a research-only compound under the same framework as other unapproved reference chemicals. Use outside a research context, and any use by competitive athletes, sits outside the legal line.

Several research peptides we list — including BPC-157, TB-500, GHRPs, and IGF-1 LR3 — are listed on the WADA Prohibited List under classes S0 (unapproved substances) and S2 (peptide hormones and growth factors). They are prohibited at all times, in and out of competition.

Honestly: it depends on the molecule. EMA-approved peptide drugs (semaglutide, tirzepatide, tesamorelin, thymalfasin in some jurisdictions) have multi-year safety datasets. Unapproved research peptides — BPC-157, TB-500, Melanotan II, Epithalon — have limited or no long-term human data.

Bring both the lyophilised vial and the bacteriostatic water to room temperature, equalise pressure with a sterile vented needle, then inject the solvent slowly down the side of the vial. Swirl gently — never shake — until clear, and refrigerate at 2–8 °C.

The calculation is peptide mass (mg) ÷ desired concentration (mg/mL) = volume of bacteriostatic water in mL. For example, a 5 mg vial at 1 mg/mL needs 5 mL; at 2 mg/mL, 2.5 mL. Every Peptyds product page carries a suggested reconstitution volume tuned to the vial size.

Most lyophilised peptides reconstituted with bacteriostatic water remain stable for 28–30 days at 2–8 °C, protected from light. A handful of short, fragile sequences — Epithalon among them — drop to roughly 14 days. Never freeze a reconstituted vial.

Across published trials and case series, the most frequent reported events are injection-site reactions (redness, induration, transient discomfort), headache, mild nausea, and temporary fatigue. GLP-1 and dual-agonist class peptides add dose-dependent gastrointestinal effects.

Peptides are not appropriate for anyone who is pregnant, nursing, planning conception, under 18, managing active cancer, or on immunosuppressants — and competitive athletes governed by WADA must avoid every peptide on the prohibited list. Anyone with a personal or family history of melanoma should specifically avoid melanocortin-receptor agonists.